S. Korea Officials Not Considering Tamiflu Compulsory License
This article was originally published in PharmAsia News
Executive Summary
The South Korean government is under pressure to follow the practice of some other Asian countries and issue a compulsory license to allow a generic version of Roche's antiviral flu drug, Tamiflu (oseltamivir). The country has not had a serious debate over compulsory licensing since 2005 when the Korea FDA asked several local drug makers if they could manufacture a generic of Tamiflu to treat avian flu. Sixteen South Korean companies submitted data showing they could make the drug almost immediately. A Health Ministry official said a compulsory license was never debated within the government, but some medical professionals say such a move should be considered to deal with the current H1N1 flu outbreaks. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.